Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
Deep learning-based MRI analysis reveals Lewy body co-pathology accelerates brain aging in Alzheimer's disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ahmadi Babak, Armstrong Melissa, Asken Breton M, Reisi-Gahrooei Mostafa, Babajani-Feremi Abbas, Alzheimer's Disease Neuroimaging Initiative, Australian Imaging Biomarkers and Lifestyle flagship study of ageing
Аннотация
INTRODUCTION: Lewy body (LB) co-pathology is common in Alzheimer's disease (AD), yet its in vivo impact on neurodegeneration remains unclear.
METHODS: We trained a 3D-DenseNet on multi-cohort T1-weighted magnetic resonance imaging (MRI) from cognitively unimpaired individuals to estimate brain age (BA) and applied it to cognitively impaired Alzheimer's Disease Neuroimaging Initiative (ADNI) participants stratified by cerebrospinal fluid (CSF) p-tau181/Aβ42 (AD) and α-synuclein seed amplification assay (LB) status into: AD+LB+, AD+LB-, AD-LB+, and AD-LB-. We compared baseline and longitudinal brain-age gap (BAG), identified saliency-derived anatomical contributors, assessed regional atrophy and cognition, and evaluated whether BAG explains LB-related clinical decline within AD.
RESULTS: The model robustly captured normative aging. AD+LB+ exhibited the greatest and fastest-increasing BAG, with saliency maps emphasizing regions that also showed steeper longitudinal atrophy and concordant cognitive decline, and BAG mediated a substantial portion of LB-related cognitive impairment within AD+.
DISCUSSION: LB co-pathology confers an additional neurodegenerative burden in AD, underscoring the importance of combined biomarker assessment and targeted interventions.
METHODS: We trained a 3D-DenseNet on multi-cohort T1-weighted magnetic resonance imaging (MRI) from cognitively unimpaired individuals to estimate brain age (BA) and applied it to cognitively impaired Alzheimer's Disease Neuroimaging Initiative (ADNI) participants stratified by cerebrospinal fluid (CSF) p-tau181/Aβ42 (AD) and α-synuclein seed amplification assay (LB) status into: AD+LB+, AD+LB-, AD-LB+, and AD-LB-. We compared baseline and longitudinal brain-age gap (BAG), identified saliency-derived anatomical contributors, assessed regional atrophy and cognition, and evaluated whether BAG explains LB-related clinical decline within AD.
RESULTS: The model robustly captured normative aging. AD+LB+ exhibited the greatest and fastest-increasing BAG, with saliency maps emphasizing regions that also showed steeper longitudinal atrophy and concordant cognitive decline, and BAG mediated a substantial portion of LB-related cognitive impairment within AD+.
DISCUSSION: LB co-pathology confers an additional neurodegenerative burden in AD, underscoring the importance of combined biomarker assessment and targeted interventions.